Enrofloxacin sustained-release tablets for pets and preparation method for same

A technology of enrofloxacin and sustained-release tablets, which is applied in the field of enrofloxacin sustained-release tablets for pets and its preparation, can solve the problems of excessive fluctuation of blood drug concentration and great influence on the treatment effect, and reduce injuries risk, improve the effect of clinical treatment, and the effect of simple production process

Inactive Publication Date: 2013-03-06
RINGPU TIANJIN BIOLOGICAL PHARMA
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Patent (CN101190194A, disclosed on June 4, 2008) provides a kind of enrofloxacin chewable tablet for dogs and cats, which mainly consists of enrofloxacin, aspartame, oral glucose, skimmed milk powder, magnesium stearate, starch, Dextrin and other components, the main advantage is that it enhances the palatability of enrofloxacin and facilitates clinical administration, but frequent administration can easily cause excessive fluctuations in blood drug concentration, which has a greater impact on the therapeutic effect during clinical treatment
The patent (CN1177300A, published on March 25, 1998) provides a preparation method of enrofloxacin injection or infusion, which is mainly composed of enrofloxacin and polyhydroxy carboxylic acid. This patent has the advantages of easy injection and stability , but it cannot solve the problem of difficult drug administration in clinical

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Enrofloxacin sustained-release tablets for pets and preparation method for same
  • Enrofloxacin sustained-release tablets for pets and preparation method for same
  • Enrofloxacin sustained-release tablets for pets and preparation method for same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Party:

[0020]

[0021]

[0022] Preparation:

[0023] A. Grind enrofloxacin, hydroxypropyl methylcellulose or stearic acid, starch, and lactose respectively, pass through a 100-mesh sieve, mix well, and set aside for later use;

[0024] B, adding povidone in 80% aqueous ethanol solution to dissolve, as adhesive, for subsequent use;

[0025] C. Add the prepared adhesive to the mixed raw and auxiliary materials, granulate, dry to ensure that the moisture content is below 5%, and pass through a 20-mesh sieve;

[0026] D. Grind the remaining auxiliary materials, pass through a 100-mesh sieve, add to the prepared granules, mix evenly, and press into tablets.

Embodiment 2

[0028] Party:

[0029]

[0030] Preparation:

[0031] A. Grind enrofloxacin, hydroxypropyl cellulose, polyethylene glycol 6000, starch and lactose respectively, pass through a 100-mesh sieve, mix well, and set aside for later use;

[0032] B, adding povidone in 80% aqueous ethanol solution to dissolve, as adhesive, for subsequent use;

[0033] C. Take 75% of the mixed raw and auxiliary materials and add the prepared binder, granulate, and dry to ensure that the moisture content is below 5% and pass through a 20-mesh sieve;

[0034] D. After passing through a 100-mesh sieve, the remaining mixed raw and auxiliary materials are added to the prepared granules, mixed evenly, and pressed into tablets.

Embodiment 3

[0035] Example 3 Stability test

[0036] 1 Materials and methods

[0037] 1.1 Material test drug: Enrofloxacin sustained-release tablets prepared according to Example 1-A, Example 1-B, Example 1-C, Example 2-A, Example 2-B respectively; control Medicine: According to the patent (CN101190194A, published on June 4, 2008), self-made enrofloxacin chewable tablets for dogs and cats, the content is 5mg.

[0038] 1.2 Methods Take 25 tablets of the test drug and the reference drug respectively. According to the "Technical Specification for Stability Test of Veterinary Drugs (Trial)", the accelerated test of the drug was carried out for six months. Sampling for content determination.

[0039] 2 Test results

[0040] Example 2 Drug stability test results (n=4)

[0041]

[0042] The results showed that the drug stability of the enrofloxacin sustained-release tablets prepared in Example 1-A, Example 1-B, Example 1-C, Example 2-A, Example 2-B was significantly better than The stabi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses enrofloxacin sustained-release tablets for pets and a preparation process for the same. The enrofloxacin sustained-release tablets disclosed by the invention are stable in medicine release and safe in medication, as well as is composed of enrofloxacin, a sustained-release or controlled-release material, a filler, an adhesive, a lubricant and a flavouring agent. The enrofloxacin sustained-release tablets prepared by the preparation process disclosed by the invention have the characteristics of being convenient to administrate, lasting in action and stable in curative effect.

Description

technical field [0001] The invention belongs to the field of veterinary drug preparations, in particular to an enrofloxacin sustained-release tablet for pets and a preparation method thereof. Background technique [0002] Enrofloxacin, also known as Enrofloxacin, is a fluoroquinolone drug specially used for animals. It is a broad-spectrum antibiotic drug that can be used to treat respiratory, gastrointestinal, and genitourinary tract infections caused by bacteria and mycoplasma, as well as purulent skin diseases. . The mechanism of action of the drug is to selectively act on the DNA gyrase of prokaryotes, thereby making the synthesis of mRNA and protein out of control, blocking the replication of bacterial DNA, and causing bacterial death. Enrofloxacin is rapidly absorbed after administration in animals, and the drug concentration in tissue is higher than that in plasma after reaching a steady state. Therefore, enrofloxacin can be used as a systemic therapeutic drug for sys...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K31/496A61P31/04
Inventor 魏德宝谷健周英超
Owner RINGPU TIANJIN BIOLOGICAL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap